pharmaphorum May 15, 2024
AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity – the ability of the brain to respond to changes.
The two companies will work together on the development of a “next-generation” of psychiatric medicines, although – for now – the drugs themselves and the target indications are being kept under wraps. other than to say they include mood and anxiety disorders.
AbbVie has also promised up to $1.95 billion in option fees and milestone payments for a series of neuroplastogens, therapies that tap into the mechanisms of the current wave of psychedelic medicines, but are a different class of compound designed to reduce the...
Today's Sponsors
Today's Sponsor